. Show Affiliations »
Abstract
Mesh: See more » Antibodies, Monoclonal, Humanized/adverse effectsAntibodies, Monoclonal, Humanized/therapeutic useAntineoplastic Agents, Immunological/adverse effectsAntineoplastic Agents, Immunological/therapeutic useDrug ApprovalHumansMedical Oncology/standardsMolecular Targeted Therapy/standardsNeoplasms/drug therapyNeoplasms/immunologyNeoplasms/pathologyPrecision Medicine/standardsProgrammed Cell Death 1 Receptor/antagonists & inhibitorsProgrammed Cell Death 1 Receptor/immunologyStandard of Care/standardsUnited StatesUnited States Food and Drug Administration/standards
Substances: See more » Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalPDCD1 protein, humanProgrammed Cell Death 1 Receptorpembrolizumab
Year: 2017 PMID: 28677559 DOI: 10.1016/S1470-2045(17)30474-6
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316